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a b s t r a c t
Background: Environmental enteropathy (EE), the adverse impact of frequent and numerous enteric infections on
the gut resulting in a state of persistent immune activation and altered permeability, has been proposed as a key
determinant of growth failure in children in low- and middle-income populations. A theory-driven systems
model to critically evaluate pathways through which enteropathogens, gut permeability, and intestinal and systemic inﬂammation affect child growth was conducted within the framework of the Etiology, Risk Factors and
Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development
(MAL-ED) birth cohort study that included children from eight countries.
Methods: Non-diarrheal stool samples (N = 22,846) from 1253 children from multiple sites were evaluated for a
panel of 40 enteropathogens and fecal concentrations of myeloperoxidase, alpha-1-antitrypsin, and neopterin.
Among these same children, urinary lactulose:mannitol (L:M) (N = 6363) and plasma alpha-1-acid glycoprotein
(AGP) (N = 2797) were also measured. The temporal sampling design was used to create a directed acyclic graph
of proposed mechanistic pathways between enteropathogen detection in non-diarrheal stools, biomarkers of intestinal permeability and inﬂammation, systemic inﬂammation and change in length- and weight- for age in children 0–2 years of age.
Findings: Children in these populations had frequent enteric infections and high levels of both intestinal and systemic inﬂammation. Higher burdens of enteropathogens, especially those categorized as being enteroinvasive or
causing mucosal disruption, were associated with elevated biomarker concentrations of gut and systemic inﬂammation and, via these associations, indirectly associated with both reduced linear and ponderal growth. Evidence
for the association with reduced linear growth was stronger for systemic inﬂammation than for gut inﬂammation; the opposite was true of reduced ponderal growth. Although Giardia was associated with reduced growth,
the association was not mediated by any of the biomarkers evaluated.
Interpretation: The large quantity of empirical evidence contributing to this analysis supports the conceptual
model of EE. The effects of EE on growth faltering in young children were small, but multiple mechanistic
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pathways underlying the attribution of growth failure to asymptomatic enteric infections had statistical support
in the analysis. The strongest evidence for EE was the association between enteropathogens and linear growth
mediated through systemic inﬂammation.
Funding: Bill & Melinda Gates Foundation.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

1. Introduction
Traditionally, the evaluation of pathogenicity from enteric infections in the host has focused on the evaluation of deﬁned diarrheal or acute gastrointestinal illnesses and the health outcomes
associated with such illness perceived as binary, that is, either
death or survival. It has been posited that the host response to frequent enteric infections alters the gut in a way that adversely affects the health status of the host even in the absence of diarrhea
or acute gastrointestinal illness. The consequences of this altered
host phenotype may have long term effects on child health and development potential. This condition is known as environmental
enteropathy (EE). A proposed consequence of EE is reduced linear
growth in children (Lunn, 2000; Keusch et al., 2013; Keusch et al.,
2014), and EE may explain the less than expected effectiveness of
nutritional interventions to improve growth in developing populations (Lunn et al., 1991; Humphrey, 2009; Korpe & Petri, 2012;
Kosek et al., 2014). Several mechanisms have been proposed to explain how EE results in poorer nutritional status by reducing functional capacities of the gut. These include reduced absorptive
capacity (Kelly et al., 2004; Menzies et al., 1999), increased permeability (Lunn et al., 1991), and chronic intestinal and systemic inﬂammation with resulting metabolic changes that affect nutrient
and micronutrient availability and utilization (Campbell et al.,
2003; Kosek et al., 2013).
Multiple physiological mechanisms by which enteropathogens can
disrupt gut functioning have been identiﬁed (Guerrant et al., 1999;
Berkes et al., 2003; Beltinger et al., 2008; Viswanathan et al., 2009;
Kamada et al., 2013; Brown et al., 2015) although the long term consequences in settings where exposure to enteropathogens is intense and
continuous (Platts-Mills et al., 2015) are poorly understood. Populations
in low- and middle-income countries are also subject to other causes of
growth failure, including inadequate dietary intake and frequent overt
illness, any of which may inﬂuence both EE biomarkers and observed
growth outcomes.
The collection of non-invasive biomarkers of EE is expanding, with
different markers characterizing different aspects of gut physiology
and integrity. The most widely used EE biomarker is the
lactulose:mannitol (L:M) dual sugar test for intestinal permeability
(Menzies et al., 1999; Denno et al., 2014), which has been used to demonstrate that altered gut permeability is related to the risk of stunting
and is prevalent in environments with poor sanitation (Lunn et al.,
1991; Lin et al., 2013; Weisz et al., 2012). Other EE bioassays available
include fecal markers of gut inﬂammation (Campbell et al., 2004), intestinal growth factors (Peterson et al., 2013), and plasma markers of bacterial translocation (Naylor et al., 2015). Additionally, an increasing set
of markers are becoming available that encompass systemic inﬂammation and amino acid and lipid metabolism (Campbell et al., 2003;
Mondal et al., 2012; Hashimoto et al., 2012; Mayneris-Perxachs et al.,
2016; Semba et al., 2016). Aligning the pathways indicted by this
expanding collection of biomarkers with enteric infections and growth
in early infancy and childhood across different populations is the subject
of considerable current effort (Kosek et al., 2013; Peterson et al., 2013;
Prendergast & Kelly, 2012).
The Etiology, Risk Factors and Interactions of Enteric Infections
and Malnutrition and the Consequences for Child Health and Development (MAL-ED) study was designed to assess the role of
enteropathogens and other factors in growth faltering from birth to

two years across eight sites (MAL-ED Network Investigators, 2014a).
A central hypothesis of MAL-ED is that gut injury resulting in disruption of normal physiology is the key route by which enteropathogens
contribute to malnutrition. Here, we use a causal systems model (a
directed acyclic graph [DAG]) to test key theoretical pathways of
the EE conceptual model and examine how enteropathogen infection
results in impaired physical growth in infancy and early childhood
(Fig. 1).
2. Methods
2.1. Study Design and Population
The MAL-ED study, conducted in eight diverse sites on three continents: Bangladesh (Dhaka: BGD), India (Vellore: INV), Nepal (Bhaktapur:
NEB), and Pakistan (Naushero Feroze: PKN) in Southern Asia; Brazil (Fortaleza: BRF) and Peru (Loreto: PEL) in Latin America; and South Africa
(Venda: SAV) and Tanzania (Haydom: TZH) in Sub-Saharan Africa. The
study design is described in detail elsewhere (MAL-ED Network
Investigators, 2014b). In brief, children were enrolled within 17 days of
birth, but excluded if they had a birth weight b 1500 g, were very ill, or
were non-singleton; or if their mother was b16 years of age. Approximately 10 children were enrolled per month per site, with the goal of
retaining ≥200 per site at 24 months of age (after loss to follow up).
Data collection methods are described elsewhere for illness and treatment (Richard et al., 2014), infant feeding (Caulﬁeld et al., 2014), and
stool microbiology (Houpt et al., 2014). Each site obtained ethical approval from their respective institutions and written consent was obtained
from participants.
Non-diarrheal stool samples collected monthly in the ﬁrst year and
quarterly in the second year were evaluated for N40 pathogens using
a standardized approach (Houpt et al., 2014). In addition to analyzing
total number of pathogens detected per stool, we also categorized pathogens into ﬁve groups based on pathophysiology. Group I included

Fig. 1. Conceptual model of the associations between pathogens, markers of gut function
and inﬂammation, systemic inﬂammation and growth.
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Fig. 2. Timeline for collection of stool, urine, and blood samples and their respective biomarker assays that relate to changes in growth Z-scores.

viruses that cause limited mucosal disturbances (rotavirus, adenovirus
and astrovirus). Group II included bacteria that are enteroinvasive or
cause extensive mucosal disruption (Campylobacter, Shigella, Salmonella, Plesiomonas, Yersinia, enteroaggregative E. coli (EAEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC) and Aeromonas).
Group III was enterotoxigenic E. coli (ETEC), which is a cause of secretory diarrhea with only limited mucosal changes. Cryptosporidium (Group
IV) and Giardia (Group V) were considered independently as organisms
have both been shown to be associated with linear growth failure and
prolonged and persistent carriage.
Three fecal biomarkers relating to aspects of gut inﬂammation and
immunity (“local inﬂammation” in Fig. 1) were evaluated using the
same non-diarrheal stool samples assayed for enteropathogens:(Kosek
et al., 2014; Kosek et al., 2013) (1) myeloperoxidase (MPO, ng/mL) as
a marker of neutrophil activity in the intestinal mucosa (Alpco, Salem,
NH, USA); (Keusch et al., 2013) neopterin (NEO, nmol/L) to indicate Thelper cell 1 activity (GenWay Biotech, San Diego, CA, USA); and
(Keusch et al., 2014) alpha-1-antitrypsin (AAT, mg/g) to indicate protein loss and intestinal permeability (Biovendor, Candler, NC, USA). Because diarrhea leads to stool dilution, fecal biomarker values were
excluded if proximate to diarrheal symptoms (within seven days
prior). Similarly, stools collected the day of or the day following the
L:M test were excluded as this test is an osmotic laxative.
In addition to fecal biomarkers, urinary L:M testing (“gut permeability” in Fig. 1) was performed at three, six, nine, and 15 months, as described elsewhere (Kosek et al., 2014). Urine samples were processed
using high-performance liquid chromatography and pulsed amperometric detection or ion chromatography (depending on study site).
The results were converted into a sample-based Z-score (LMZ) to minimize age and sex trends. Data from the BRF cohort were used as the internal reference standard.
Finally, systemic inﬂammation was evaluated at seven, 15, and
24 months using alpha-1-acid glycoprotein (AGP) concentration in
plasma. Incidence of acute lower respiratory infection (ALRI), diarrhea,
fever (associated with neither ALRI nor diarrhea), and a composite for
any of the three categorized illness episodes in the seven or 14 days preceding the blood collection were drawn from bi-weekly maternal reports. These were used to examine the inﬂuence of recent, nondiarrheal, overt illness on AGP concentration.
Monthly length (cm) and weight (kg) measures (Lohmann et al.,
1988) were converted to Z-scores (LAZ, WAZ respectively) based on
WHO 2006 standards (World Health Organization, 2006). The change
(Δ) in LAZ and WAZ for each child (ﬁnal minus initial value for each period) served as the outcome in all analyses, controlling for the initial
value. Intense quality assurance review procedures identiﬁed bias within the PKN length measures; therefore, these data were excluded from

the system analysis. PKN biomarker data were however, included in
the evaluation of associations between pathogens and biomarkers.

2.2. Statistical Analysis
First, to maximally leverage the large size of the MAL-ED dataset and
to place our results in the context of previous studies, we analyzed relationships between pathogens and fecal biomarker concentrations, between pathogens and LMZ scores, between LMZ scores and changes in
anthropometry, and among potential sources of systemic inﬂammation
not associated with gut enteropathy.
Linear mixed effects models were constructed to examine cross-sectional associations between individual pathogens and concentrations of
each fecal biomarker. Speciﬁcally, the log concentrations of MPO, NEO,
and AAT were modeled as functions of stool consistency (a categorical
description of stool liquidity), linear and quadratic terms for child age
(to capture age-related trends), the presence of individual pathogens
(adjusting for the presence of other pathogens), and a random intercept
for child nested in site (McCormick et al., 2016).
The same model structure was extended to evaluate associations between pathogen presence and LMZ scores, limiting the analyses to nondiarrheal stools collected at the same age as the L:M test. Additionally,
changes in anthropometry (ΔLAZ and ΔWAZ) over three, six, and nine
month windows starting at each L:M assay were evaluated as a function
of the LMZ scores. Individual children nested within their respective site
were treated as a random intercept to account for clustering at both the
individual child and site levels.
To determine whether the concentration of AGP was related to overt
illness in the seven or 14 days preceding blood collection, another linear
mixed effects model was constructed with log-transformed AGP concentration as a function of age and illness (i.e., the presence of diarrhea,
Table 1
The number of samples collected and with complete data to yield observations in individual children included in the system model. The analysis of individual biomarkers includes
all available observations.
Age 1 (4 ≤ m ≤ 11)

Samples

Children

Blood
Urine
Non-diarrheal stools
Anthropometry
Total
Excluding PKN
Complete data

Age 2 (12 ≤ m ≤ 21)

Collected

Complete

Collected

Complete

1503
1767
4481
15,272
2001
1734
1059

1476
1601
4285
15,257

1536
1706
2821
16,232
1873
1617
1070

1503
1535
2676
16,215
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Table 2
Observed characteristics of the subset of the MAL-ED population with complete data that were included in the system model. The mean and standard deviation (SD) of the continuous
variables (anthropometry and the biomarkers) are shown along with the percentage of the discrete variables that were positive for at least one pathogen in each of the groups or the presence of maternally reported symptoms of ALRI and fever preceding the AGP assay and the percentage of stools that were coincident with different food intakes.
Continuous variables

LAZ start
ΔLAZ
WAZ start
ΔWAZ
log(MPO)
log(NEO)
log(AAT)
log(AGP)
LMZ

Age 1

Age 2

Discrete variables

Mean

±SD

Mean

±SD

−0.97
−0.06
−0.53
−0.04
8.90
7.69
−0.89
4.61
0.35

1.13
0.63
1.15
0.50
1.26
1.08
0.93
0.40
0.87

−1.05
−0.20
−0.61
−0.13
8.33
7.30
−1.17
4.63
0.40

1.05
0.47
1.21
0.41
1.27
1.30
1.13
0.36
1.12

fever, and ALRI). A random intercept for child nested in site was
included.
In addition to these linear regressions and given that disease systems
composed of different interacting pathways lend themselves to causal
graphical modeling (e.g., Fig. 1) (Pearl, 1995; Greenland et al., 1999)
we constructed a DAG model to test hypothetical pathways between
the presence of enteropathogens, biomarker concentrations, and changes in LAZ and WAZ. Combining all factors into a single system allowed
for the explicit partition of associations into direct and indirect
pathways.
Variables within this system were represented as conditionally independent, multivariate, generalized linear mixed models such that the
probability of observing a given value for each variable was a function
of other variables connected within the system (indicated by arrows
in Fig. 1). To account for heterogeneity between sites, random effects
for both site and child were added at every node. The DAG analysis focused on two time periods, 4 ≤ months ≤ 11 (Age 1) and 12 ≤ months
≤ 21 (Age 2), using the data collection schedule shown in Fig. 2 to capture temporal associations between events marked by the biomarkers.
Speciﬁcally, pathogen data was coincident with collection of the fecal
biomarkers (MPO, NEO, and AAT). Their collection preceded collection
of L:M as alterations in gut permeability are a hypothesized result of inﬂammation. Measures of systemic inﬂammation then followed. The
temporal window then extended beyond biomarker collection to assess
associations with subsequent growth.
The net effects of both direct and indirect pathways were simulated
from the ﬁtted DAG. Sensitivities of ΔLAZ and ΔWAZ to changes in each
biomarker were examined by ﬁxing each biomarker to its observed
mean concentration as well as one standard deviation higher or lower.
The ΔLAZ and ΔWAZ were then simulated and the difference between
their mean values when biomarkers were raised or lowered relative to
when they were held at mean concentration were estimated.
The model was run in JAGS (version 3.4.0) to perform Markov Chain
Monte Carlo simulations (Plummer, 2003). Further details are given in
the Appendix.

Pathogens

ALRI
Fever

Age 1

Group 1
Group 2
Group 3
Group 4
Group 5

Age 2

% Positive

% Positive

6.85
56.76
6.85
3.43
3.36
1.71
28.26

9.11
65.86
10.21
5.10
18.35
1.94
24.18

and AGP (Table 1 and Table 2). Among the over 20,000 non-diarrheal
stools tested for concentrations of MPO, NEO, and AAT, there was a
trend for the concentration of each biomarker to decrease with increasing age. Within individual children; however, biomarker concentrations
were highly variable across time, with intra-class correlations (ICC) of
0·07, 0·03, and 0·06 for MPO, NEO, and AAT respectively. Pearson correlation coefﬁcients between the biomarkers were low (≤0·2) suggesting they measured different physiological insults.
A comparison of associations between enteropathogens and the
fecal biomarkers revealed that pathophysiological groups tended to
show similar trends, with some prevalent pathogens being associated
with either higher or lower biomarker concentrations (e.g., Campylobacter and EAEC were associated with higher concentrations of MPO
and AAT, while Giardia was associated with lower concentrations of all
three fecal biomarkers). The associations were more pronounced in
some of the rarer pathogens (e.g., Yersinia enterocolitica was strongly associated with increased MPO and decreased NEO concentrations the
few times it was detected) (Fig. 3). These exploratory models assumed
additive effects of pathogens, though in many instances more than
one pathogen was detected.
LMZ tended to be higher, indicating increased permeability, in children with pathogens detected, especially those with positive tests for
Cryptosporidium (0·34 ± 0·08 for mean ± standard deviation, N =
134) and Giardia (0·20 ± 0·05, N = 457) (Fig. 3). However, there
was no statistical support for LMZ relating to changes in either LAZ or
WAZ (Table 3).
With respect to systemic inﬂammation, approximately half the measures of AGP were elevated (N 100 mg/dL), indicating common subclinical inﬂammation. Across the two time points when AGP was measured,

2.3. Role of the Funding Source
The Bill & Melinda Gates Foundation did not play any role in the
writing of the manuscript nor did the funders have of the study had
any role in the study design, data collection, analysis, or interpretation
of study results. The corresponding author had full access to all the
data in the study and had ﬁnal responsibility for the decision to submit
for publication.
3. Results
Data from the entire cohort were included in the linear analyses for
associations between pathogens and fecal biomarkers and LMZ, the
changes in anthropometry following the L:M test, and between illness

Fig. 3. Effect of pathogens on the three fecal biomarkers (N non-diarrheal stools = 27,931)
and the L:M test (N urine samples = 4476). The color represents the coefﬁcient from a
linear mixed effects model with pathogens found in the same stool as the fecal
biomarkers or during the same month as the L:M test. Cells with crosses are not
signiﬁcant (p ≥ 0.05). Pathogens, within their groups (I˗V), are sorted by prevalence
(high to low, left to right). In addition to the presence of individual pathogens, age was
included using both linear and quadratic terms, stool consistency was included in the
biomarker models, and child nested in site was included as a random intercept.
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Table 3
The relationship between the LMZ and changes in LAZ and WAZ over a three, six, or nine month period from the age of the L:M test. L:M tests were performed at three, six, nine, and
15 months. Child nested in study site was considered a random intercept to account for repeated measures and site heterogeneity.
Mean effect (±standard error)
ΔLAZ (months post L:M test)

Constant (3 m L:M)
Constant (6 m L:M)
Constant (9 m L:M)
Constant (15 m L:M)
LAZ/WAZ at start
L:M Z-score (3 m)
L:M Z-score (6 m)
L:M Z-score (9 m)
L:M Z-score (15 m)
N
N children
N sites
Variance (child)
Variance (site)
Variance (Residual)

ΔWAZ (months post L:M test)

3m

6m

9m

3m

6m

9m

−0.21 (0.08)⁎,⁎⁎
−0.12 (0.02)⁎⁎⁎
−0.24 (0.02)⁎⁎⁎
−0.25 (0.02)⁎⁎⁎
−0.24 (0.01)⁎⁎⁎

−0.71 (0.20)⁎⁎⁎
−0.21 (0.02)⁎⁎⁎
−0.33 (0.02)⁎⁎⁎
−0.40 (0.02)⁎⁎⁎
−0.65 (0.01)⁎⁎⁎

−1.08 (0.25)⁎⁎⁎
−0.19 (0.02)⁎⁎⁎
−0.27 (0.02)⁎⁎⁎
−0.33 (0.02)⁎⁎⁎
−0.82 (0.01)⁎⁎⁎

−0.21 (0.08)⁎
−0.12 (0.02)⁎⁎⁎
−0.24 (0.02)⁎⁎⁎
−0.25 (0.02)⁎⁎⁎
−0.24 (0.01)⁎⁎⁎

−0.71 (0.20)⁎⁎⁎
−0.21 (0.02)⁎⁎⁎
−0.33 (0.02)⁎⁎⁎
−0.40 (0.02)⁎⁎⁎
−0.65 (0.01)⁎⁎⁎

−1.08 (0.25)⁎⁎⁎
−0.19 (0.02)⁎⁎⁎
−0.27 (0.02)⁎⁎⁎
−0.33 (0.02)⁎⁎⁎
−0.82 (0.01)⁎⁎⁎

0.00 (0.02)
−0.03 (0.02)
−0.01 (0.02)
−0.02 (0.02)
5343
1650
7
0.03
0.05
0.29

−0.01 (0.01)
0.03 (0.02)
−0.00 (0.02)
0.00 (0.02)
5213
1591
7
0.37
0.27
0.18

0.00 (0.01)
−0.01 (0.02)
−0.02 (0.02)
0.00 (0.02)
5117
1563
7
0.61
0.44
0.13

0.00 (0.02)
−0.03 (0.02)
−0.01 (0.02)
−0.02 (0.02)
5343
1650
7
0.03
0.05
0.29

−0.01 (0.01)
0.03 (0.02)
−0.00 (0.02)
0.00 (0.02)
5213
1591
7
0.37
0.27
0.18

0.00 (0.01)
−0.01 (0.02)
−0.02 (0.02)
0.00 (0.02)
5117
1563
7
0.61
0.44
0.13

⁎⁎⁎ p b 0·001.
⁎⁎ p b 0·01.
⁎ p b 0·05.

high concentrations were dispersed between children rather than focused in an identiﬁable subset (ICC 0·16). Across 4257 AGP assays, neither symptoms of ALRI (which was uncommon at the time of the two
blood draws) nor diarrhea were associated with concentrations of
AGP (Table 4). Maternally-reported fever in the 14 days prior to the
blood draw was associated with increased AGP concentration. Only
the subset of MAL-ED children with complete data (i.e. with no missing
observations across all variables) was included in the DAG (Table 1).
Within the systems model, which included the pathogen groups, all
biomarkers, and both growth outcomes, the invasive bacteria (Group II)
showed positive associations with MPO for both ages (Fig. 4). Additionally, ETEC (Group III) infection was associated with lower concentrations of AAT at Age 1 and higher concentrations of MPO in older Age 2
children. At Age 1, AAT concentration was positively associated with
LMZ, while MPO was negatively associated with LMZ (Fig. 4). In the
older age period, MPO concentration was positively associated with
AGP, while NEO was negatively associated with AGP.
Regarding associations between biomarkers and the two growth
outcomes, ΔLAZ and ΔWAZ, the systems model revealed direct negative
relationships between MPO and both ΔLAZ and ΔWAZ during Age 1 and

Table 4
The impact of recent overt symptoms on the log concentration of AGP based on
samples at seven, 15, and 24 months. A linear mixed model of log(AGP) as a function of the presence or absence of overt symptoms in the 14 days preceding the
blood draw. Child nested in site was treated as a random intercept.
Variable

Mean (±standard error)

Constant
Diarrhea
Fever
ALRI
Age (months)
Diarrhea ∗ age
Fever ∗ age
ALRI ∗ age

4.58 (0.07)⁎⁎⁎,⁎⁎,⁎
0.04 (0.05)
0.21 (0.04)⁎⁎⁎
−0.14 (0.07)
−0.00 (0.00)
0.00 (0.00)
0.00 (0.00)
0.02 (0.00)⁎⁎⁎

N
N children
N sites
Variance (child)
Variance (site)
Variance (residual)

4257
1801
8
0.01
0.03
0.15

⁎⁎⁎ p b 0·001.
⁎⁎ p b 0·01.
⁎ p b 0·05.

negative associations between AAT and ΔWAZ in both age groups (Fig.
4) (i.e., the higher the concentration of MPO or AAT, the more restricted
the growth over the respective period). There was no statistical support
for an association between LMZ and either ΔLAZ or ΔWAZ in the system
model (or for lactulose excretion, data not shown). Higher AGP concentrations were associated with decreased ΔLAZ at both ages and with
ΔWAZ during Age 1 (Fig. 4). Because enteropathogens, particularly
those associated with enteroinvasion or mucosal disruption (Group
II), were directly related to increased MPO, they were thereby indirectly
related to reduced growth. Giardia was associated directly with reduced
growth, but not with the fecal biomarkers.
The effects of higher or lower biomarker concentrations relative to
their observed means on ΔLAZ and ΔWAZ over each age period are
shown in Fig. 5. None of the biomarkers had large mean effects on the
average ΔLAZ or ΔWAZ. Of the effects on ΔLAZ, changing the log(AGP)
concentration by ± 1SD produced the greatest difference (± 0·05
mean ΔLAZ), but little effect on the mean ΔWAZ (±0·02 ΔWAZ) relative to the observed concentration of log(AGP). Changing the MPO concentration by ±1SD had the second largest impact on ΔLAZ (+0·04 or
−0·03 for a decrease or increase in log(MPO) concentration respectively). The effect of increasing MPO concentration on ΔWAZ was marginally larger (− 0·05 ± 0·03), after which AAT had the second biggest
impact on ΔWAZ (+0·04 when decreased and −0·06 when log(AAT)
was increased by 1SD).

4. Discussion
The systems model presented here is the ﬁrst effort to explicitly
combine enteropathogen exposure and different EE biomarkers (i.e.,
for gut permeability, gut inﬂammation, and systemic inﬂammation)
into a single system and examine prospectively the pathways through
which they relate to growth, thus providing an important proof of principal for a poorly deﬁned condition. The temporal nature of the data allows for the exploration of causality and for the natural history of the
biologic processes being measured to be interpreted with rigor. Our
model is informed by a substantial quantity of structured longitudinal
data on enteropathogens in non-diarrheal stools, illness history, intestinal inﬂammation and permeability, systemic inﬂammation, and growth
across seven populations. The number of repeated measures over time
and measures within the same individual is a particular strength of
these data. Enteropathogen presence changes the concentration of contemporary biomarkers of gut immunity (NEO), inﬂammation (MPO),
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Fig. 4. The model results for (a) Age 1 (4 ≤ months ≤ 11) and (b) Age 2 (12 ≤ months ≤ 21) using functional pathogen groupings and the speciﬁc pathways indicated by the individual fecal
biomarkers as well as LMZ and AGP. Arrows show those relationships that had statistical support based on the 95% credibility interval. Red arrows indicate positive associations and blue
arrows show negative associations. The pathogen groups reﬂect 1) viruses; 2) invasive bacteria; 3) non-invasive bacteria; 4) Cryptosporidium; and 5) Giardia.

and permeability (AAT and LMZ). We ﬁnd additional evidence that both
enteropathogens and gut inﬂammation relate to systemic
inﬂammation.
Our results yield several important ﬁndings. First, children living in
these eight countries with differing epidemiologic settings have consistently and strikingly high concentrations of MPO (nearly 5–10 times the
those seen in the USA) (Saiki, 1998) and nearly twice the concentration
of AAT (Meyers et al., 1985). They also have notable elevations in AGP
and intestinal permeability (L:M) that are two to three times higher
than values in healthy populations (Kremer et al., 1988). Additionally,
there was a high burden of enteropathogens detected even in the absence of overt diarrhea episodes (Platts-Mills et al., 2015). But most importantly, related MAL-ED analyses have demonstrated that, in the

diverse epidemiologic settings of the study, growth velocities were
low (MAL-ED Network Investigators, n.d.-a) leading to an increased
prevalence of stunting by two years (MAL-ED Network Investigators,
n.d.-b). The evidence we present here suggests that EE as measured by
these markers contributes to, but does not appear to be the predominant driver of growth faltering.
As hypothesized, pathogen presence in non-diarrheal stool samples
was associated with higher fecal MPO; this ﬁnding was also noted for
AAT, although the AAT ﬁndings were evident only in younger children
(aged 4˗11 months). When fecal biomarkers were evaluated for associations with individual pathogens, stronger signals of inﬂammation were
noted in response to the rarely detected Shigella and Yersinia and the
ubiquitous Campylobacter. The differential importance of pathogens in

Fig. 5. Sensitivity analysis of the DAG model (Fig. 4) to explore the effect of increasing (triangles) or decreasing (squares) the concentration of different biomarkers on mean ΔLAZ and
ΔWAZ at the two age periods (Age 1, black; Age 2, gray). Symbols indicate the mean difference (lines, ±1 standard deviation) in the mean simulated ΔLAZ and ΔWAZ when
biomarkers are changed ±1 standard deviation compared to a simulation using the mean observed biomarker value (i.e., the dotted horizontal line shows a difference of zero).
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inducing EE is an area that requires additional attention, especially
given the availability of newer technologies that allow for broad coverage and quantiﬁcation of enteropathogens (Platts-Mills et al., 2015),
and other strategies for determining which microbial taxa are inducing
mucosal response in the gut (MAL-ED Network Investigators, n.d.-b).
Such studies will enhance our understanding of the possible impact of
etiology-speciﬁc interventions on EE.
Each of the three fecal biomarkers in this analysis have previously
been associated with an elevated risk of stunting in the ﬁrst year of
life (George et al., 2015). Similar results have been found in other studies (Lin et al., 2013; Naylor et al., 2015). Here, we also ﬁnd support for
direct effects of gut inﬂammation (i.e., as measured by the three fecal
biomarkers) on ΔLAZ or ΔWAZ. The evidence for an effect of systemic
inﬂammation (i.e., as measured by AGP) is more compelling than that
of the EE biomarkers. We found no evidence for an association between
augmented intestinal permeability (i.e., as measured by LMZ) and future growth. Despite the popular use of L:M as a test of EE in cross sectional studies, its predictive power for future growth is less clear. While
many studies have shown the L:M ratio to be associated with the contemporaneous LAZ (Lunn et al., 1991; Goto et al., 2009; Campbell et
al., 2002), others have found (as we did) that it was not predictive of
change in LAZ of children (Lin et al., 2013; Weisz et al., 2012). Given
that AAT was associated with both gut permeability and subsequently
to changes in growth (especially WAZ, both Age 1 and 2), it is possible
that AAT more reliably reﬂects changes (or more severe changes) in
permeability than the L:M test. The polar surface area of AAT greatly exceeds that of lactulose, and the size of the permeability defect may be
important to delineate in greater detail using alternate probes. It is
worth noting that other MAL-ED data (i.e., non-growth data) indicate
the L:M test is predictive of impaired efﬁcacy of oral polio vaccine
(MAL-ED Network Investigators, n.d.-c). As such, the L:M test may capture other domains of EE not examined in these analyses.
Our results suggest that reductions in the exposure to pathogens, in
particular to invasive bacteria that increase MPO, could reduce systemic
inﬂammation (AGP). Recent evidence from another cohort study similarly highlighted the importance of systemic inﬂammation (Naylor et
al., 2015). AGP interacts with bacterial lipopolysaccharide (LPS)
(Moore et al., 1997), which is an indicator of bacterial translocation,
and LPS bound to AGP is more rapidly cleared from the body than unbound LPS. Consequently, it was surprising to see that neither LMZ
nor AAT were associated with AGP, as permeability leading to bacterial
translocation has been a principal hypothesized component of EE (Lunn
et al., 1991). Other markers of bacterial translocation are needed to conﬁrm these ﬁndings.
Although our model indicates that speciﬁc enteropathogens alter
gut inﬂammation and permeability, the effect sizes of the pathways
from biomarkers to growth were smaller than anticipated (Humphrey,
2009; Brown et al., 2015). Based on available evidence, the contribution
of EE to growth deﬁcits as captured in these biomarkers is small relative
to the accrued growth deﬁcits in these populations (Lunn et al., 1991;
Humphrey, 2009; MAL-ED Network Investigators, n.d.-a; MAL-ED
Network Investigators, n.d.-b). The use of additional biomarkers or combinations of biomarkers and growth phenotypes (Naylor et al., 2015) or
inclusion of metabolic markers may help to identify stronger support for
links between the interactions of enteropathogen pressure and
undernutrition on growth failure. Additionally, on-going work in this
study population to understand links between the microbiome
(Subramanian et al., 2014), host metabolism (Mayneris-Perxachs et
al., 2016), and growth will expand our understanding of how microbial
populations affect the nutritional status in these populations (Lunn,
2000; Brown et al., 2015; Kau et al., 2015; Blanton et al., 2016; Kosek
et al., 2016).
The analytical framework described here is the ﬁrst attempt to explicitly examine causal pathways of EE. Our results demonstrate that exposure to enteropathogens results in abnormal gut permeability,
inﬂammation, systemic immune activation, and growth failure, but

suggest that additional work incorporating other critical features of
host metabolic status and the microbiome are needed to explain the
gap between the insults attributable to EE and the observed cumulative
acquired deﬁcits of growth in children in these populations.
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